304 related articles for article (PubMed ID: 29221990)
21. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
22. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
23. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
24. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
25. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract][Full Text] [Related]
26. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
Front Immunol; 2018; 9():1044. PubMed ID: 29868007
[TBL] [Abstract][Full Text] [Related]
28. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
29. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
30. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
31. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
32. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
[TBL] [Abstract][Full Text] [Related]
33. Treatment landscape of metastatic pancreatic cancer.
De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
[TBL] [Abstract][Full Text] [Related]
34. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Ghosn M; Ibrahim T; Assi T; El Rassy E; Kourie HR; Kattan J
World J Gastroenterol; 2016 Dec; 22(46):10124-10130. PubMed ID: 28028360
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Du J; Gu J; Li J
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
[TBL] [Abstract][Full Text] [Related]
36. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
[TBL] [Abstract][Full Text] [Related]
39. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
40. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
